share_log

Stifel Reiterates Buy on Cue Biopharma, Maintains $8 Price Target

Benzinga ·  Jun 15, 2023 08:42

Stifel analyst Stephen Willey reiterates Cue Biopharma (NASDAQ:CUE) with a Buy and maintains $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment